Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: GenomeWeb s Weekly Personnel Roundup of the Genomics Sector: Feb 27, 2002

NEW YORK, Feb. 27 - German proteomics company Protagen on Wednesday said it has appointed Christoph H ls to be CEO and head of the company's management board.

 

Protagen also said that Helmut Meyer will become chief scientific officer, and Martin Bl ggel will be chief operating officer and head of bioinformatics. Both men are company founders.

 

Lastly, Alex Kleeman has be chosen to be the new head of Protagen's board of directors, the company said. Achim Riemann was tapped to replace him.

 


 

Privately held proteomics firm BSI Proteomics has promoted Mark Sawicki to the post of director of structural biology, the company said on Feb. 25.

 

Sawicki has been a senior structural biologist at the Gaithersburg, Md.-based firm since he joined it 2000, BSI said.

 

In his new position, Sawicki will "oversee all scientific aspects ... including setting the research agenda, acting as chief scientific liaison to companies that BSI partners with, and directing all research programs," according to the firm.

 

Before joining BSI, Sawicki was a faculty research director at the Center for Advanced Research in Biotechnology at the University of Maryland.

 


 

Pharsight has tapped Michael Perry to replace Art Reidel as president and chief executive officer, the company said on Feb. 25. Reidel will remain with Pharsight as chairman of the board.

 

Perry comes to Pharsight from Baxter Global Biopharmaceuticals, where he was the worldwide head of research and development for two years. He also was president and CEO of SyStemix, between 1997 and 2000, and Genetic Therapy, from 1998 to 2000. Both companies are subsidiaries of Sandoz/Novartis.

 

"Mike Perry brings to Pharsight a unique combination of extensive operational background and deep experience in, and vision for, how pharmaceutical research and development can be improved," Reidel said in a statement.

 


 

AxCell Biosciences, a unit of Cytogen, has appointed Axel Ullrich to its scientific advisory board, the company said on Feb. 21. 

 

Ullrich, who specializes in cellular communication and cancer, has been the director and head of the Max-Planck institute for biochemistry since 1988. He also was a co-founder of Sugen, in 1991, and Axxima, in 1998.

 


 

Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] PEOPLE, a roundup of personnel comings and goings in genomics, appears each Wednesday.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.